Miconazole, a pharmacological barrier to skin fungal infections

Introduction: Miconazole (MCZ) is a time-honored antifungal of the imidazole class. MCZ exerts a multipronged effect on fungi. It inhibits the cytochrome P450 complex, including the 14α-demethylase enzyme required for ergosterol biosynthesis, in fungal cell membranes. In addition, intracellular accumulation of toxic methylated sterols occurs and the synthesis of triglycerides and phospholipids is altered. Disturbances in oxidative and peroxidative enzyme activities lead to an intracellular toxic concentration of hydrogen peroxide. As a result, intracellular organelle destruction then leads to cell necrosis. Farnesol synthesis stimulated in Candida spp. prevents the yeast-to-mycelium formation. MCZ is further active against Gram-positive bacteria. Areas covered: This review aims at revisiting the MCZ antifungal activity in dermatomycoses. Expert opinion: MCZ's wide spectrum of activity appears noteworthy. The full pharmacological profile of MCZ indicates its fungistatic profile through its effect on ergosterol biosynthesis. In addition, it exhibits a fungicidal effect against a number of fungal species, due to hydrogen peroxide accumulation. MCZ is characterized by high safety, efficacy and versatility, and a unique, multifaceted nature of activity in the treatment of dermatomycoses.

[1]  G. Piérard,et al.  Established and emerging oral antifungals in dermatology , 2013 .

[2]  S. Cheng,et al.  Development of miconazole nitrate containing chitosan microcapsules and their anti-Aspergillus niger activity , 2012, Journal of microencapsulation.

[3]  T. Foster,et al.  Miconazole Induces Fungistasis and Increases Killing of Candida albicans Subjected to Photodynamic Therapy † , 2012, Photochemistry and photobiology.

[4]  R. Musioł,et al.  Azole antimycotics--a highway to new drugs or a dead end? , 2012, Current medicinal chemistry.

[5]  M. Kovac,et al.  Miconazole and nystatin used as topical antifungal drugs interact equally strongly with warfarin , 2012, Journal of clinical pharmacy and therapeutics.

[6]  R. N. Brogden,et al.  Miconazole: A Review of its Antifungal Activity and Therapeutic Efficacy , 2012, Drugs.

[7]  Y. Sawada,et al.  Warfarin and miconazole oral gel interactions: analysis and therapy recommendations based on clinical data and a pharmacokinetic model , 2011, Journal of clinical pharmacy and therapeutics.

[8]  J. Perfect,et al.  Addressing current medical needs in invasive fungal infection prevention and treatment with new antifungal agents, strategies and formulations , 2011, Expert opinion on emerging drugs.

[9]  Jeannina A Smith,et al.  Management of oropharyngeal candidiasis with localized oral miconazole therapy: efficacy, safety, and patient acceptability , 2011, Patient preference and adherence.

[10]  R. Prasad,et al.  The Quorum-Sensing Molecule Farnesol Is a Modulator of Drug Efflux Mediated by ABC Multidrug Transporters and Synergizes with Drugs in Candida albicans , 2011, Antimicrobial Agents and Chemotherapy.

[11]  H. Nelis,et al.  Superoxide Dismutases Are Involved in Candida albicans Biofilm Persistence against Miconazole , 2011, Antimicrobial Agents and Chemotherapy.

[12]  M. Ghannoum,et al.  Repeated exposure of Candida spp. to miconazole demonstrates no development of resistance , 2011, Mycoses.

[13]  Christine D Wu,et al.  In vitro synergism between berberine and miconazole against planktonic and biofilm Candida cultures. , 2011, Archives of oral biology.

[14]  Z. Dvořák.  Drug-drug interactions by azole antifungals: Beyond a dogma of CYP3A4 enzyme activity inhibition. , 2011, Toxicology letters.

[15]  R. Bensadoun,et al.  Miconazole mucoadhesive tablet for oropharyngeal candidiasis , 2011, Expert review of anti-infective therapy.

[16]  A. Franks,et al.  Hyperprothrombinemia as a Result of a Possible Warfarin and Intravaginal Miconazole Interaction , 2010, Southern medical journal.

[17]  M. Ghannoum,et al.  Antifungal activity of miconazole against recent Candida strains , 2010, Mycoses.

[18]  M. Mazzotti,et al.  Miconazole nanosuspensions: Influence of formulation variables on particle size reduction and physical stability. , 2010, International journal of pharmaceutics.

[19]  E. Puijenbroek,et al.  Interaction between topical miconazole and coumarins , 2010, European Journal of Clinical Pharmacology.

[20]  N. Musaji.  Antifungal drug resistance: not all azoles are equal , 2010, Expert review of anti-infective therapy.

[21]  N. Karami,et al.  Antimicrobial activity of topical skin pharmaceuticals - an in vitro study. , 2010, Acta dermato-venereologica.

[22]  S. Grether-Beck,et al.  Involvement of Lipid Rafts and Caveolins in UVA Signaling , 2009 .

[23]  Ana Espinel-Ingroff,et al.  Antifungal drug resistance mechanisms , 2009, Expert review of anti-infective therapy.

[24]  D. Elston.  Topical antibiotics in dermatology: emerging patterns of resistance. , 2009, Dermatologic clinics.

[25]  G. Piérard,et al.  Updating Corneofungimetry: A Bioassay Exploring Dermatomycoses and Antifungal Susceptibility , 2009, Mycopathologia.

[26]  J. Arrese,et al.  Clinicopathologic presentations of dermatomycoses in cancer patients , 2008, Journal of the European Academy of Dermatology and Venereology : JEADV.

[27]  A. Barasch,et al.  Miconazole revisited: new evidence of antifungal efficacy from laboratory and clinical trials. , 2008, Future microbiology.

[28]  Aditya K. Gupta,et al.  Update in Antifungal Therapy of Dermatophytosis , 2008, Mycopathologia.

[29]  B. Zee,et al.  Is topical antimycotic treatment useful as adjuvant therapy for flexural atopic dermatitis: randomized, double‐blind, controlled trial using one side of the elbow or knee as a control , 2008, International journal of dermatology.

[30]  G. Piérard,et al.  Novelties in the multifaceted miconazole effects on skin disorders. , 2008, Expert opinion on pharmacotherapy.

[31]  G. Dive,et al.  Theoretical and experimental investigations on miconazole/cyclodextrin/acid complexes: molecular modeling studies. , 2007, International journal of pharmaceutics.

[32]  W. Du,et al.  Miconazole Induces Changes in Actin Cytoskeleton prior to Reactive Oxygen Species Induction in Yeast* , 2007, Journal of Biological Chemistry.

[33]  L. Eichenfield,et al.  Absorption and efficacy of miconazole nitrate 0.25% ointment in infants with diaper dermatitis. , 2007, Journal of drugs in dermatology : JDD.

[34]  G. Piérard,et al.  [How I treat....A stoutness-associated intertrigo]. , 2007, Revue medicale de Liege.

[35]  J. Heeres,et al.  Antifungal azoles for skin disorders , 2006 .

[36]  A. Fothergill.  Miconazole: a historical perspective , 2006, Expert review of anti-infective therapy.

[37]  J. Quiring,et al.  Topical miconazole nitrate ointment in the treatment of diaper dermatitis complicated by candidiasis. , 2006, Cutis.

[38]  J. Ausma,et al.  Azoles: mode of antifungal action and resistance development. Effect of miconazole on endogenous reactive oxygen species production in Candida albicans , 2006 .

[39]  E. Warshaw,et al.  Prevention of onychomycosis reinfection for patients with complete cure of all 10 toenails: results of a double-blind, placebo-controlled, pilot study of prophylactic miconazole powder 2%. , 2005, Journal of the American Academy of Dermatology.

[40]  G. Piérard,et al.  Tribological and mycological consequences of the use of a miconazole nitrate-containing paste for the prevention of diaper dermatitis: an open pilot study , 1996, European Journal of Pediatrics.

[41]  J. Ausma,et al.  Involvement of lipid rafts in antifungal mode of action of miconazole , 2005 .

[42]  K. Nickerson,et al.  Defined Anaerobic Growth Medium for Studying Candida albicans Basic Biology and Resistance to Eight Antifungal Drugs , 2004, Antimicrobial Agents and Chemotherapy.

[43]  K. Nickerson,et al.  Enhanced Production of Farnesol by Candida albicans Treated with Four Azoles , 2004, Antimicrobial Agents and Chemotherapy.

[44]  C. Osborne,et al.  Antifungal drug response in an in vitro model of dermatophyte nail infection. , 2004, Medical mycology.

[45]  J. Arrese,et al.  Treatment Failures and Relapses in Onychomycosis: A Stubborn Clinical Problem , 2003, Dermatology.

[46]  N. Tsuji,et al.  Endogenous Reactive Oxygen Species Is an Important Mediator of Miconazole Antifungal Effect , 2002, Antimicrobial Agents and Chemotherapy.

[47]  Steven Phillips,et al.  Diaper Dermatitis: A Therapeutic Dilemma. Results of a Double‐Blind Placebo Controlled Trial of Miconazole Nitrate 0.25% , 2001, Pediatric dermatology.

[48]  G. Piérard,et al.  Biometrological assessment of the preventive effect of a miconazole spray powder on athlete's foot , 1996, Clinical and experimental dermatology.

[49]  C. Tur,et al.  In-vitro antifungal activity of sertaconazole, bifonazole, ketoconazole, and miconazole against yeasts of the Candida genus. , 1996, The Journal of antimicrobial chemotherapy.

[50]  L. Fernández,et al.  Systemic contact dermatitis from miconazole , 1996, Contact dermatitis.

[51]  G. Piérard,et al.  Comparative study of the activity and lingering effect of topical antifungals. , 1993, Skin pharmacology : the official journal of the Skin Pharmacology Society.

[52]  H. Baes.  Contact sensitivity to miconazole with ortho‐chloro cross‐sensitivity to other imidazoles , 1991, Contact dermatitis.

[53]  R. Happle,et al.  Contact allergy to miconazole , 1988, Contact dermatitis.

[54]  R. Fromtling.  Overview of medically important antifungal azole derivatives , 1988, Clinical Microbiology Reviews.

[55]  F. Odds,et al.  Improved method for estimation of azole antifungal inhibitory concentrations against Candida species, based on azole/antibiotic interactions. , 1986, Journal of medical and veterinary mycology : bi-monthly publication of the International Society for Human and Animal Mycology.

[56]  M. Borgers,et al.  Cytochemical localization of NADH oxidase in Candida albicans. , 1977, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[57]  M. Borgers,et al.  An Ultrastructural and Cytochemical Study of Candida aIbicans after in Vitro Treatment with Imidazoles , 1976, Mykosen.

[58]  M. Borgers,et al.  The ultrastructure of Candida albicans after in vitro treatment with miconazole. , 1974, Sabouraudia.

[59]  J. V. van Cutsem,et al.  Miconazole, a broad-spectrum antimycotic agent with antibacterial activity. , 1972, Chemotherapy.